

Central Nervous System Drugs Market Trends Show Increasing Collaborations Between Manufacturers

The Business Research Company's Central Nervous System Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030

LONDON, GREATER LONDON, UK, July 9, 2021 /EINPresswire.com/ -- Many central nervous system drug manufacturers are collaborating with other manufacturers in the industry to share technical knowledge and improve product quality. These agreements are helping anti-epileptics


drugs manufacturers broaden their products and services. For instance, in January 2017, Japan's Takeda Pharmaceuticals collaborated with New York-based biotech company Ovid Therapeutics to develop TAK-935, a drug for the treatment of rare epilepsy disorders in children. Also, Israel based D-Pharm LTD. and China based Jiangsu NHWA Pharmaceutical Co. Ltd. are co-developing DP-VPA, an anti-epileptic drug. In October 2016, UCB Pharmaceuticals signed a partnership agreement with Evotec for the research and development of drugs for nervous disorders such as epilepsy, Parkinson's, and Alzheimer's diseases.

The major players covered in the [global central nervous system drugs market](#) are Biogen Inc, F. Hoffmann-La Roche Ltd, Johnson & Johnson, Pfizer Inc, Novartis AG.

Read More On The Global Central Nervous System Drugs Market Report:

<https://www.thebusinessresearchcompany.com/report/central-nervous-system-drugs-global-market-report-2020-30-covid-19-implications-and-growth>

The global central nervous system drugs market is expected to grow from \$125.28 billion in 2020 to \$126.89 billion in 2021 at a compound annual growth rate (CAGR) of 1.3%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges.



The market is expected to reach \$163.05 billion in 2025 at a CAGR of 6%.

North America is the largest region in the global CNS pharmaceuticals market, accounting for 48% of the market in 2020. Asia Pacific is the second largest region, accounting for 22% of the global CNS drugs market. Africa was the smallest region in the CNS therapeutics market.

The global central nervous system drugs market is segmented by type into analgesics, anti-parkinson drugs, anesthetics, anti-epileptics, other CNS drugs, by distribution channel into hospital pharmacies, retail pharmacies/ drug stores, others, by route of administration into oral, parenteral, others, by drug classification into branded drugs, generic drugs, by mode of purchase into prescription-based drugs, over-the-counter drugs.

[Central Nervous System Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030](#) is one of a series of new reports from The Business Research Company that provides central nervous system drugs market overview, forecast central nervous system drugs market size and growth for the whole market, central nervous system drugs market segments, and geographies, central nervous system drugs market trends, central nervous system drugs market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request For A Sample Of The Global Central Nervous System Drugs Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=2141&type=smp>

Here Is A List Of Similar Reports By The Business Research Company:

Brain And Neuroimaging Devices Global Market Report 2021: COVID 19 Growth And Change to 2030

<https://www.thebusinessresearchcompany.com/report/brain-and-neuroimaging-devices-global-market-report-2020-30-covid-19-growth-and-change>

Brain Tumor Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030

<https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report>

Alzheimer's Disease Treatment Global Market Report 2021: COVID 19 Growth And Change To 2030

<https://www.thebusinessresearchcompany.com/report/alzheimers-disease-treatment-global-market-report-2020-30-covid-19-growth-and-change>

Anti-Parkinson Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030

<https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report-2020-30-covid-19-growth-and-change>

Anesthetics Global Market Report 2021: COVID 19 Implications And Growth to 2030

<https://www.thebusinessresearchcompany.com/report/anesthetics-global-market-report>

Pharmaceutical Drugs Market - By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030

<https://www.thebusinessresearchcompany.com/report/pharmaceutical-drugs-market>

Interested to know more about [The Business Research Company?](https://www.thebusinessresearchcompany.com/)

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

The Business Research Company

Email: info@tbrc.info

Follow us on LinkedIn: <https://bit.ly/3b7850r>

Follow us on Twitter: <https://bit.ly/3b1rmjS>

Check out our Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/545845612>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable

in today's world. Please see our Editorial Guidelines for more information.

© 1995-2021 IPD Group, Inc. All Right Reserved.